Provera

Provera (medroxyprogesterone acetate) is a prescription progestin medication widely used in gynecology and endocrinology for managing various hormone-related conditions. As a synthetic form of the natural hormone progesterone, it provides targeted therapeutic action for abnormal uterine bleeding, amenorrhea, endometrial protection during estrogen therapy, and certain hormone-sensitive conditions. With decades of clinical use and extensive research supporting its efficacy, Provera remains a cornerstone in hormonal management protocols when administered under proper medical supervision.

Features

• Contains medroxyprogesterone acetate as active ingredient
• Available in 2.5 mg, 5 mg, and 10 mg oral tablets
• Synthetic progestin with predictable pharmacokinetic profile
• FDA-approved for multiple gynecological indications
• Manufactured under strict pharmaceutical quality standards
• Multiple therapeutic dosing regimens available

Benefits

• Effectively controls abnormal uterine bleeding and restores menstrual regularity
• Provides endometrial protection during estrogen replacement therapy
• Induces withdrawal bleeding in cases of secondary amenorrhea
• Offers predictable hormonal response with established dosing protocols
• Supported by extensive clinical research and decades of therapeutic use
• Enables targeted management of hormone-sensitive conditions

Common use

Provera is primarily prescribed for the treatment of secondary amenorrhea (absence of menstrual periods in women who have previously menstruated), abnormal uterine bleeding due to hormonal imbalance without organic pathology, and as part of hormone replacement therapy in postmenopausal women with an intact uterus to prevent endometrial hyperplasia. It may also be used off-label for other conditions requiring progestin therapy, including endometriosis management and certain cases of premature labor, though these uses require specialized medical supervision.

Dosage and direction

Dosage varies significantly based on indication and patient characteristics. For secondary amenorrhea: 5-10 mg daily for 5-10 days, with withdrawal bleeding typically occurring within 3-7 days after completion. For abnormal uterine bleeding: 5-10 mg daily for 5-10 days beginning on day 16 of cycle, with bleeding usually occurring within 3-7 days after stopping medication. For endometrial protection during estrogen therapy: typically 2.5-10 mg daily for 12-14 days per month in cyclical therapy or 2.5-5 mg daily in continuous combined regimens. Tablets should be taken at the same time each day with water, with or without food. Dosage adjustments may be necessary based on individual response and medical history.

Precautions

Patients should undergo thorough medical evaluation before initiating therapy, including assessment of cardiovascular risk factors, liver function, and bone density when appropriate. Regular monitoring of blood pressure, weight, and clinical response is recommended during treatment. Use with caution in patients with history of depression, asthma, diabetes, migraine, seizure disorders, or cardiac dysfunction. Patients should be advised that this medication may cause dizziness or drowsiness and to avoid activities requiring mental alertness until response is established. Long-term use requires periodic reevaluation of risk-benefit ratio.

Contraindications

Provera is contraindicated in patients with known hypersensitivity to medroxyprogesterone acetate or any component of the formulation; known or suspected pregnancy; undiagnosed abnormal genital bleeding; known or suspected hormone-dependent neoplasia; active thrombophlebitis or current or past history of thromboembolic disorders; missed abortion; severe liver dysfunction or disease; and as a diagnostic test for pregnancy.

Possible side effect

Common side effects may include breakthrough bleeding, spotting, changes in menstrual flow, amenorrhea, breast tenderness, nausea, headache, dizziness, fatigue, weight changes, acne, hirsutism, and emotional lability. Less frequently reported effects include thromboembolic disorders, retinal thrombosis, optic neuritis, mental depression, insomnia, somnolence, alopecia, rash, pruritus, edema, and changes in libido. Rare but serious potential adverse effects include thrombotic disorders, hepatic dysfunction, and possible increased risk of breast cancer with long-term use.

Drug interaction

Provera may interact with aminoglutethimide, potentially decreasing medroxyprogesterone levels. Concurrent use with other hormonal contraceptives or hormone replacement therapy requires careful monitoring. Medications that induce hepatic enzymes (including rifampin, barbiturates, carbamazepine, phenytoin, and St. John’s wort) may reduce efficacy. Anticoagulant therapy may require adjustment. Laboratory test interactions may occur with endocrine and liver function tests. Always inform healthcare providers of all medications, including over-the-counter products and supplements.

Missed dose

If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next dose. Do not double the dose to make up for a missed one. For specific dosing regimens (particularly cyclic therapy), contact the prescribing physician for guidance if a dose is missed, as the management may vary based on the timing and treatment indication.

Overdose

No serious adverse effects have been reported following acute overdose. Large doses may produce nausea and vomiting, and withdrawal bleeding may occur in females. There is no specific antidote; treatment should be symptomatic and supportive. Medical attention should be sought if large quantities are ingested, particularly in children.

Storage

Store at controlled room temperature (20-25°C or 68-77°F), with excursions permitted between 15-30°C (59-86°F). Keep container tightly closed and protect from light and moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Properly discard any unused medication after treatment completion.

Disclaimer

This information is for educational purposes only and does not constitute medical advice. Provera is a prescription medication that should be used only under the supervision of a qualified healthcare professional. Individual response to therapy may vary, and treatment decisions should be based on comprehensive medical evaluation. Always follow the specific instructions provided by your prescribing physician and refer to the official prescribing information for complete details.

Reviews

Clinical studies and decades of therapeutic use demonstrate Provera’s effectiveness in managing hormone-related conditions when appropriately prescribed. Many patients experience significant improvement in symptoms with proper dosing and monitoring. However, individual experiences vary, and some patients may not tolerate the medication well or may experience side effects that necessitate discontinuation. Patient satisfaction often correlates with proper indication selection, adequate patient education, and appropriate management of expectations regarding therapeutic outcomes and potential side effects.